Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - neuroinflammation
4
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Selective PAD2 Inhibitors for Neuroprotection in Traumatic Brain Injury
SHORT DESCRIPTION Novel PAD2-selective inhibitor platform targeting
neuroinflammation
to support both acute neuroprotection and long-term functional recovery as a first-in-class treatment of traumatic brain injury. INVENTORS Hasan Alam* Northwestern University Feinberg School of Medicine, Department of Surgery (Trauma...
Published: 4/27/2026
|
Updated: 4/27/2026
|
Inventor(s):
Keywords(s):
CNS - Central Nervous System
,
CVA - Cerebrovascular Accident
,
Neurodegenerative disease
,
Neuroinflammation
,
Neurologic disease
,
Neurology
,
Small molecule
,
Targeted therapy
,
TBI - Traumatic brain injury
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
JNK Inhibitors Targeting Bergmann Glia Inflammation to Mitigate Spinocerebellar Ataxia and Other Neurodegenerative Disorders
SHORT DESCRIPTION Novel therapeutic strategy targeting Bergmann glia inflammation using JNK inhibition for treatment of spinocerebellar ataxia type 1 (SCA1) and other neurodegenerative disorders. INVENTORS Puneet Opal* Northwestern University Feinberg School of Medicine, Professor of Neurology Chandrakanth...
Published: 4/16/2026
|
Updated: 4/14/2026
|
Inventor(s):
Keywords(s):
Bergmann glia inflammation
,
Neurodegenerative disease
,
Neuroinflammation
,
Neurologic disease
,
Neurology
,
Rare diseases
,
SCA - Spinocerebellar ataxia
,
Small molecule
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and neurodegenerative disorders
NU 2025-113 (NU 2016-137, NU 2018-176, NU 2019-179, NU 2023-007, NU 2024-250, NU 2025-038) INVENTORS Richard Silverman Weinberg College of Arts and Sciences, Department of Chemistry SHORT DESCRIPTION Novel highly selective neuronal nitric oxide synthase (nNOS) inhibitors for targeted therapy of melanoma and other cancers with high expression...
Published: 4/30/2026
|
Updated: 4/1/2026
|
Inventor(s):
Keywords(s):
ALS - Amyotrophic Lateral Sclerosis
,
AUTM26C1
,
BIAUTM1
,
Cancer/Oncology
,
Cardiology and Cardiovascular disease
,
Immunodeficiency
,
Immunology
,
Immunotherapy
,
Melanoma
,
Neurodegenerative disease
,
Neuroinflammation
,
nNOS
,
Small molecule
,
Targeted therapy
,
Therapeutics
Category(s):
Life Sciences > Therapeutics
Use of Repurposed Compounds for the Treatment of Alzheimer’s Disease
Summary: The NIA seeks co-development partners and/or licensees for the further pre-clinical and clinical development of TTI-101, hydroxychloroquine, and Dasatinib to treat Alzheimer’s disease. Description of Technology: There are no effective treatments for Alzheimer’s disease (AD), a progressive brain disease that slowly destroys a...
Published: 4/23/2026
|
Updated: 8/2/2023
|
Inventor(s):
Madhav Thambisetty
Keywords(s):
Alzheimer’s Disease
,
ApoE
,
Apolipoprotein-E
,
Aβ
,
FYN
,
National Institute on Aging
,
Neuroinflammation
,
NIA
,
STAT3
,
Tau Phosphorylation
,
Thambisetty
,
YES1
Category(s):
Collaboration Sought > Collaboration
,
Application > Therapeutics
,
TherapeuticArea > Neurology
,
Collaboration Sought > Licensing